NME
TEVA icon

Notis-McConarty Edward’s Teva Pharmaceuticals TEVA Stock Holding History

Notis-McConarty Edward’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-17,221
Closed -$690K – 112
2013
Q4 		$690K Buy
+17,221
New +$678K 0.48% 62

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

Notis-McConarty Edward's TEVA Position: Q1 2014 in Review

Notis-McConarty Edward sold out of Teva Pharmaceuticals (TEVA) in Q1 2014, closing a stake of 17,221 shares — an estimated $690K sold.

Notis-McConarty Edward first reported a position in TEVA in Q4 2013 and held it in 1 quarter. The position peaked at $690K in Q4 2013. 770 funds tracked by Wall St. Rank hold TEVA as of Q1 2014.

  • Notis-McConarty Edward reported no remaining Teva Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Notis-McConarty Edward sold 17,221 Teva Pharmaceuticals shares in Q1 2014, an estimated $690K.
  • Notis-McConarty Edward first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • Notis-McConarty Edward's Teva Pharmaceuticals position peaked at $690K in Q4 2013.
  • 770 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2014.

Based on Notis-McConarty Edward's 13F filing for Q1 2014, filed 29 May 2014.